Comparative Pharmacology
Head-to-head clinical analysis: CEFOTETAN versus CEFUROXIME SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTETAN versus CEFUROXIME SODIUM.
CEFOTETAN vs CEFUROXIME SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
Cefuroxime sodium is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1 to 2 g intravenously or intramuscularly every 12 hours. For severe infections, up to 2 g every 12 hours for 5-10 days.
750 mg to 1.5 g IV or IM every 8 hours; maximum 6 g per day.
None Documented
None Documented
3-4.5 hours (6-8 hours in renal impairment).
Clinical Note
moderateCefotetan + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefotetan."
Clinical Note
moderateCefotetan + Ethanol
"The risk or severity of adverse effects can be increased when Cefotetan is combined with Ethanol."
Clinical Note
moderateCefotetan + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefotetan."
Clinical Note
moderateCefotetan + Carbocisteine
Terminal elimination half-life: 1.2 hours (range 1-2 hours) in patients with normal renal function; prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min); dosing adjustment required for CrCl <30 mL/min
Renal (80-90% unchanged), biliary (small amount, up to 20% in bile), fecal (<5%).
Renal (95% unchanged via glomerular filtration and tubular secretion); biliary/fecal (minimal, <5%)
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The risk or severity of adverse effects can be increased when Cefotetan is combined with Carbocisteine."